<?xml version='1.0' encoding='UTF-8'?><xml><records><record><source-app name="HighWire" version="7.x">Drupal-HighWire</source-app><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Hitt Nichols, Emma</style></author></authors><secondary-authors><author><style face="normal" font="default" size="100%">Stangier, Joachim</style></author></secondary-authors></contributors><titles><title><style face="normal" font="default" size="100%">Idarucizumab Reverses Dabigatran in Elderly or Renally Impaired</style></title><secondary-title><style face="normal" font="default" size="100%">MD Conference Express</style></secondary-title></titles><dates><year><style  face="normal" font="default" size="100%">2014</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2014-12-01 00:00:00</style></date></pub-dates></dates><pages><style  face="normal" font="default" size="100%">14-15</style></pages><abstract><style  face="normal" font="default" size="100%">In elderly or renally impaired volunteers, the antibody fragment idarucizumab rapidly and completely reversed the anticoagulation effect of dabigatran, sustained for at least 24 hours. Re-administration of dabigatran after 24 hours resulted in anticoagulation similar to that observed during initial treatment. There were no clinically relevant drug-related events; infusion-related effects were similar between arms.</style></abstract><number><style face="normal" font="default" size="100%">55</style></number><volume><style face="normal" font="default" size="100%">14</style></volume></record></records></xml>